This post-conference summary of ESMO 2022 highlights major advances in oncology across five key themes. Antibody-drug conjugates (ADCs) continued to gain momentum, driven by improved understanding of mechanisms of action and technological innovation. Clinical data showed promising efficacy for therapies such as sacituzumab govitecan in metastatic breast cancer and reinforced the role of ADCs in bladder cancer treatment, particularly in combination with checkpoint inhibitors. The conference also showcased growing interest in personalized medicine, with therapies increasingly tailored based on pathology, clinical staging, and molecular profiling. Notable findings included sotorasib demonstrating superiority over chemotherapy in KRAS G12C-mutated non-small cell lung cancer and adagrasib stren

Join for free to read